It implies that the restoration of increased cytotoxic zinc levels in the malignant cells for treatment of prostate cancer must include a process or vehicle that facilitates the entry of zinc into the ZIP1-deficent malignant cells. This evidence concerns the gene SLC39A1 and prostate cancer.